Publications by authors named "Robyn Emanuel"
Article Synopsis
- * Ruxolitinib became the first approved drug for MF, showing significant benefits in symptom relief, spleen size reduction, and survival, with more JAK2 inhibitors like fedratinib and pacritinib entering phase III testing.
- * Ongoing research is exploring various therapies, including immunomodulators and combination strategies, aiming to improve the management of MF and enhance individualized treatment plans for patients.
Background: Nonmedical use of prescription psychostimulants such as methylphenidate and amphetamine salts for the purpose of cognitive enhancement is a growing trend, particularly in educational environments. To our knowledge, no recent studies have evaluated the use of these psychostimulants in a medical academic setting.
Objective: To conduct an online census of psychostimulant use among medical students.
The quality of life (QoL) at the time of diagnosis of myeloproliferative neoplasm (MPN) has, to date, not been studied. One hundred and seventy-nine patients with MPN: 80 with essential thrombocythemia (ET), 73 with polycythemia vera (PV), 22 with primary myelofibrosis (PMF) and four with MPN undifferentiated, were included in this study. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQC30) and the MPN-Symptom Assessment Form (MPN-SAF) were used to evaluate QoL.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on developing an abbreviated symptom score (MPN-SAF TSS) to assess and track the most relevant symptoms experienced by patients with myeloproliferative neoplasms (MPNs), aiming to improve treatment outcomes.
- Analysis included 1,408 MPN patients and revealed significant differences in symptom scores across different MPN subtypes, with a strong correlation to overall quality of life and internal consistency.
- The MPN-SAF TSS showed potential as a reliable tool for measuring symptom burden in MPN patients, making it valuable for evaluating treatment responses in future studies.